文献速递肝胆胰外科

胰腺癌新辅助治疗联合手术后的复发模式与生存结局随时间的变化趋势

Trends Over Time in Recurrence Patterns and Survival Outcomes after Neoadjuvant Therapy and Surgery for Pancreatic Cancer.
PubMed 文献 · Ann Surg · 2024-03-20

该研究纳入1998至2018年间接受新辅助治疗后行根治性胰腺切除术的727例胰腺导管腺癌患者,按1998-2004、2005-2011、2012-2018三个时段比较治疗、复发部位与时机及生存。结果显示总复发率稳定(67.5%、66.1%、65.9%),85%的复发发生在术后2年内,但2012-2018队列术后第1年条件复发风险降低而第2年升高;总生存(中位30.6、33.6、48.7个月,P<0.005)和复发后生存(中位7.8、12.5、12.6个月;3年率7%、10%、20%;P<0.005)随时间改善。

要点

  • 2012-2018队列中超过80%的患者接受FOLFIRINOX或吉西他滨联合白蛋白结合型紫杉醇方案。
  • 总体复发部位和发生率稳定(67.5%、66.1%、65.9%),85%的复发发生在术后2年内。
  • 与早期队列相比,2012-2018队列术后第1年条件复发风险降低而第2年升高。

核心结论

  • 新辅助治疗方案随时间变化,复发条件风险从术后第1年向第2年转移,但复发仍常见;总生存和复发后生存随时间显著改善,反映复发疾病多学科方案改善。

研究设计与样本

  • 研究纳入1998-2018年间接受新辅助治疗后行根治性胰腺切除术的胰腺导管腺癌患者727例,按1998-2004、2005-2011、2012-2018三个队列(分别为203、251、273例)比较治疗、复发部位与时机及生存。

主要发现

  • 新辅助诱导化疗使用随时间增加,方案随时间变化,2012-2018队列中超过80%的患者接受FOLFIRINOX或吉西他滨联合白蛋白结合型紫杉醇。
  • 总体复发部位和发生率稳定(67.5%、66.1%、65.9%),85%的复发发生在术后2年内。
  • 与早期队列相比,2012-2018队列术后第1年条件复发风险降低而第2年升高。
  • 总生存随时间增加(中位30.6、33.6、48.7个月,P<0.005),由复发后总生存改善驱动(中位7.8、12.5、12.6个月;3年率7%、10%、20%;P<0.005)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We aimed to determine if advances in neoadjuvant therapy affected recurrence patterns and survival outcomes after pancreatectomy for pancreatic ductal adenocarcinoma (PDAC). BACKGROUND: Data are limited on how modern multimodality therapy affects PDAC recurrence and postrecurrence survival. METHODS: Patients who received neoadjuvant therapy followed by curative-intent pancreatectomy for PDAC during 1998-2018 were identified. Treatments, recurrence sites and timing, and survival were compared between patients who completed neoadjuvant therapy and pancreatectomy during 1998-2004, 2005-2011, and 2012-2018. RESULTS: The study included 727 patients (203, 251, and 273 in the 1998-2004, 2005-2011, and 2012-2018 cohorts, respectively). The use of neoadjuvant induction chemotherapy increased over time, and regimens changed over time, with >80% of patients treated in 2012-2018 receiving FOLFIRINOX or gemcitabine with nab-paclitaxel. Overall, recurrence sites and incidence (67.5%, 66.1%, and 65.9%) remained stable, and 85% of recurrences occurred within 2 years of surgery. However, compared with earlier cohorts, the 2012-2018 cohort had a lower conditional risk of recurrence in postoperative year 1 and a higher risk in postoperative year 2. Overall survival increased over time (median, 30.6, 33.6, and 48.7 mo, P < 0.005), driven by improved postrecurrence overall survival (median, 7.8, 12.5, and 12.6 mo; 3-year rate, 7%, 10%, and 20%; P < 0.005). CONCLUSIONS: We observed changes in neoadjuvant therapy regimens over time and an associated shift in the conditional risk of recurrence from postoperative year 1 to postoperative year 2, although recurrence remained common. Overall survival and postrecurrence survival remarkably improved over time, reflecting improved multimodality regimens for recurrent disease.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Cass SH, Tzeng CD, Prakash LR, et al. Trends Over Time in Recurrence Patterns and Survival Outcomes after Neoadjuvant Therapy and Surgery for Pancreatic Cancer. Ann Surg. 2024. PMID: 38506042. doi:10.1097/SLA.0000000000006269

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。